Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Post time 2022-1-12 15:27:42

journal：New England Journal of Medicine

Authors：Hussein A. Tawbi; Dirk Schadendorf; Evan J. Lipson; Paolo A. Ascierto; Luis Matamala; Erika Castillo Gutiérrez; Piotr Rutkowski; Helen J. Gogas; Christopher D. Lao; Juliana Janoski De Menezes; Stéphane Dalle; Ana Arance; Jean-Jacques Grob; Shivani Srivastava; Mena Abaskharoun; Melissa Hamilton; Sarah Keidel; Katy L. Simonsen; Anne Marie Sobiesk; Bin Li; F. Stephen Hodi; Georgina V. Long

Published date：2022-1-6

DOI：10.1056/nejmoa2109970

Article link：http://dx.doi.org/10.1056/nejmoa2109970

Article Source：Massachusetts Medical Society。

Remark：

Post time 2022-1-12 15:27:43

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2022-5-4 09:15:26

: This post has been completed
Completed attachments will be deleted within 24 hours.

[NEJM] Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today